BioCentury | Jun 24, 2013
Company News

Aurigene, Debiopharm deal

...Aurigene and Debiopharm announced the nomination of development candidate Debio 0617B , a small molecule targeting an...
...small molecule targeting an undisclosed oncology pathway. Aurigene said Debio will have development responsibility for Debio 0617B...
BioCentury | Dec 8, 2008
Company News

Debiopharm, Dr. Reddy's deal

Dr. Reddy's Aurigene Discovery Technologies Ltd. subsidiary granted Debiopharm exclusive, ex-Asian rights to develop and commercialize an inhibitor of an undisclosed cancer pathway, now called Debio 0617, to treat cancer. Debiopharm plans to begin a...
Items per page:
1 - 2 of 2